Infinity Pharmaceuticals Inc
NASDAQ:INFI
Infinity Pharmaceuticals Inc
Revenue
Infinity Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Infinity Pharmaceuticals Inc
NASDAQ:INFI
|
Revenue
$2.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Infinity Pharmaceuticals Inc's Revenue?
Revenue
2.6m
USD
Based on the financial report for Jun 30, 2023, Infinity Pharmaceuticals Inc's Revenue amounts to 2.6m USD.
What is Infinity Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
-16%
Over the last year, the Revenue growth was 16%. The average annual Revenue growth rates for Infinity Pharmaceuticals Inc have been 22% over the past three years , -16% over the past five years .